The webinar may provide color on the Phase I/IIa trial, but no material catalyst is announced. Traders should monitor for any data readouts or regulatory updates in future filings; this event alone is unlikely to move the stock.
Price Chart
Executive Summary
Clearmind Medicine announced a live webinar on June 10, 2026, featuring investigators from Yale and Johns Hopkins to discuss clinical data from its Phase I/IIa trial of CMND-100 (MEAI) for Alcohol Use Disorder. The press release contains no new financial data, clinical results, or regulatory milestones — it is a routine investor-relations event.
Key Facts
- Webinar scheduled for June 10, 2026, 12:00–1:00 PM EDT.
- Speakers include Dr. Anahita Bassir Nia (Yale) and Dr. Jennifer Ellis (Johns Hopkins).
- CEO Dr. Adi Zuloff-Shani will provide a clinical development and corporate update.
- No new clinical data, financial results, or regulatory decisions were disclosed in the press release.
- Company market cap is approximately $3M, reflecting early-stage biotech risk.
Financial Impact
No financial impact disclosed; webinar is a routine investor relations event.
Risk Factors
- No new clinical data or regulatory milestones announced — the webinar may not produce material news.
- Early-stage biotech with $3M market cap carries high risk of dilution or failure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307314 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $5.92 | awaiting T+60 | — | $6.07 (+2.53%) |
Oct 27, 2026 today | Press Release | $6.50 | awaiting T+60 | — | $6.07 (−6.62%) |
Oct 16, 2026 11d ago | 6-K | $6.00 | awaiting T+60 | — | $6.07 (−1.17%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $6.07 (−2.57%) |
Oct 8, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.07 (−8.03%) |
Oct 7, 2026 20d ago | 6-K | $6.60 | awaiting T+60 | — | $6.07 (−8.03%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.07 (+614.12%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.07 (+614.12%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.07 (−11.57%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.07 (+543.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers